WSJ: DOJ nearing approval of CVS-Aetna, Cigna-Express Scripts mergers

The DOJ could approve both mergers within the next few weeks, according to a WSJ report. (skpy/Flickr)

Antitrust regulators at the Department of Justice are closing in on approving two massive vertical healthcare mergers in CVS-Aetna and Cigna-Express Scripts.

Both deals could get federal approval within the next few weeks, sources told The Wall Street Journal on Wednesday.

For CVS-Aetna, part of that approval could hinge on the companies selling off some of their assets, particularly in the Part D market where consumer advocacy groups have repeatedly raised concerns about consolidation within Medicare's drug benefit program. A Kaiser Family Foundation analysis earlier this year found that the two merged companies, plus UnitedHealth Group, would cover 71% of Part D plans.


[Whitepaper] Analysis Shows Areas of Progress and Potential Cost Savings in Wound Care

Download this whitepaper to read the positive economic impact that digital solutions and patient engagement had on wound care patients in the home health setting who underwent negative pressure wound therapy (NPWT).

Suggested Articles

VenatoRx has a product that includes a compound called VNRX-5133, which when combined with cefepime may overcome forms of antibiotic resistance.

Amazon's PillPack and Surescripts, owned by CVS Health and Express Scripts, are in a dispute over access to patient medication history data.

San Francisco-based startup Forward has dubbed itself the primary care of the future. Here's a look at their latest location.